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The Cell Inﬁltrate in Lymphomatoid Papulosis Comprises a
Mixture of Polyclonal Large Atypical Cells (CD30-Positive)
and Smaller Monoclonal T cells (CD30-Negative)
To the Editor:
Lymphomatoid papulosis belongs to the spectrum of
primary cutaneous CD30-positive T cell lymphoproliferative
disorders. It is a relatively rare disorder, but has attracted
much interest because of the striking discrepancy between
its clinical behavior (characterized by recurrent nodular or
papular skin eruptions, which are sometimes necrotic but
which tend to resolve spontaneously) and its histopatholo-
gic features (an infiltrate of large atypical CD30þ T cells
with many features suggestive of malignancy) (Willemze
et al, 1997). The fact that 10%–20% of all patients develop a
secondary lymph node-based lymphoproliferative disease
(most commonly anaplastic large-cell lymphoma or Hodg-
kin’s disease) or cutaneous lymphoma (Mycosis fungoides)
all argue in favor of a link with true lymphoid malignancy
(Christensen et al, 1994; Chott et al, 1996; Wang et al, 1999).
Several studies in the past have sought to elucidate the
nature of this unusual disorder by analyzing biopsy samples
for clonal T cell receptor (TCR) gene rearrangement. Most of
these studies were performed on DNA extracted from tissue
samples, and there is a consensus that in most cases shows
a monoclonal pattern of TCR rearrangement (Whittaker et al,
1991; Davis et al, 1992; el-Azhary et al, 1994; Whittaker,
2001). Recently, a comparable study to our investigations was
carried out by Steinhoff et al (2002), who found monoclonal
patterns of TCR-gamma chain rearrangements in the CD30-
positive cells in nearly all 11 cases (PCR products in 94 cells)
studied (but who did not investigate the clonal status of the
small cell population). This investigation concluded that the
clonal population in lymphomatoid papulosis lies within this
CD30-positive large cell component (Steinhoff et al, 2002).
In the present paper we report a similar investigation, in
which we have analyzed microdissected cells from four
patients with Ly P, type A, which are characterized in Table I.
For the investigation, micromanipulation and single-cell
PCR for TCR-g and IgH-gene rearrangement was applied as
described by Gellrich et al (2001, 2003).
We expanded the scope of the investigation however by
studying not only the large CD30-positive cell population
but also the abundant population of T cells present in all Ly
P lesions. Our findings are in sharp contrast to the earlier
study, since we found that monoclonal cells were restricted
to the small CD3-positive cells whereas the large CD30-
positive cells were polyclonal (and hence, by implication,
part of a reactive process). Furthermore the small CD3-
positive cells appeared identical to clonal T cells present in
the circulation (Table I). All human studies were performed in
accordance to the Declaration of Helsinki Principles.
In one of these cases, we also found that some of the
CD30-positive cells were monoclonal B cells. This was
probably accounted for by the fact that the patient had
previously developed Hodgkin’s disease.
Our results suggest a hypothetical model in which the
skin lesions typical of type A lymphomatoid papulosis would
represent polyclonal Tcells in the skin that periodically enter
a short-lived intensive proliferative phase, but which then
die (since they lack a mechanism for survival as would be
present in a true aggressive malignant lymphoma). This
process of proliferation and morphological ‘‘transformation’’
followed by cell death is presumably undergone by reactive
T cells as part of their normal physiological response to
external stimuli (even if cells as bizarre as those seen in type
A lymphomatoid papulosis are rarely seen). Furthermore,
our findings indicate that type A lymphomatoid papulosis
patients harbor an underlying indolent clone of T cells, with
a low proliferative rate, that is not confined to the skin, being
present throughout the body (e.g. in apparently normal bone
marrow, lymph nodes, blood, and skin). We suggest that
this underlying clone arises from an ‘‘immuno-controlling’’ T
cell subset normally present at only low levels, whose
physiological role is to promote a proliferative response by
cutaneous T cells to external stimuli. Normally the rarity of
these cells would mean that only minimal skin reactions
occur, but when their numbers are magnified by clonal
expansion this response would be greatly augmented,
giving rise to the bizarre histological reactions characteristic
of type A lymphomatoid papulosis.
This concept that the clonal T cell population underlying
type A lymphomatoid papulosis arises from an ‘‘immuno-
controlling’’ T cell subset that is a very minor component of
the normal Tcell repertoire would explain the rarity of the dis-
ease, and also the fact that most benign clonal Tcell profile-
rations (e.g. as detected in older people or in non-malignant
diseases such as lichen sclerosus) do not result clinically in
lymphomatoid papulosis. If an underlying T clone that
potently influences the proliferation of other cells is present
in type A lymphomatoid papulosis, the paradox that this
T cell-derived disorder can be associated with lymphomas
of B cell origin (namely Hodgkin’s disease) would also be
explained, i.e. the clone could induce the cutaneous large
T cell proliferation typical of lymphomatoid papulosis but
also occasionally promote a proliferation of lymph node-
based large B cells to cause Hodgkin’s disease.
Copyright r 2004 by The Society for Investigative Dermatology, Inc.
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It should be added that Wood et al (1995, 2001) have also
drawn attention to the presence of small clonal T cells in
type A lymphomatoid papulosis, comparing them to the
indolent B cells present in patients with benign monoclonal
gammopathy. In our model the underlying clone of indolent
unremarkable T cells would (again mimicking a benign
monoclonal gammopathy) occasionally transform to gen-
erate an anaplastic large T cell lymphoma or Mycosis
fungoides. The fact that the background clone is ubiquitous
in the body would explain why these secondary neoplasms
are not only located in the skin. The possibility has been
raised that mutation in the TGF-b receptor gene may
contribute to this process of transformation (Schiemann
et al, 1999).
In conclusion, our findings indicate the need for further
studies of the clonal status of the large CD30-positive cells
in type A lymphomatoid papulosis compared with that of the
background infiltrate of CD30-negative T cells (and circulat-
ing T cells). Furthermore, our observations suggest a new
model of the genesis of lymphomatoid papulosis, type A;
this is at present only a theoretical proposal but it may
provide a useful basis for future studies.
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